Table 3:

Clinical Phenotypes and Module 31 Sample Clustering

		Cluster 1	Cluster 2	Cluster 3	p-value
					ANOVA	1_vs_2	1_vs_3	2_vs_3
Prevalence, n		7	27	48
Age, yr, mean ± sd		51.89 ± 7.50	48.43 ± 9.97	57.03 ± 10.40	0.0026	0.3316	0.1408	0.0008
Female sex, n (%)		5 (71)	16 (59)	32 (67)	0.7747	0.6818	1.0000	0.6182
Ever Smoker, n (%)		2 (29)	13 (48)	18 (38)	0.5799	0.4263	1	0.4651
Genotype	PiZZ off, n (%)	3 (60)	6 (25)	18 (51)	0.0851	0.2872	1.0000	0.0599
	PiMZ, n (%)	2 (40)	18 (75)	17 (49)
Therapy	PiZZ on, n (%)	2 (40)	3 (33)	13 (42)	0.8964	1.0000	1.0000	0.7171
	PiZZ off, n (%)	3 (60)	6 (67)	18 (58)
FVC (liters), mean ± sd		3.62 ± 1.23	4.06 ± 0.98	3.48 ± 1.79	0.2920	0.4052	0.7969	0.0742
FVC % predicted, mean ± sd		89.71 ± 17.49	95.15 ± 13.29	94.50 ± 21.53	0.7903	0.4656	0.5289	0.8725
FEV1 (liters) mean ± sd		2.37 ± 1.10	3.21 ± 0.89	2.55 ± 1.11	0.0236	0.0997	0.6982	0.0068
FEV1% predicted , mean ± sd		71.86 ± 28.70	91.30 ± 16.16	83.69 ± 24.59	0.1048	0.1285	0.3328	0.1113
DLCO, mean ± sd		19.60 ± 4.23	27.06 ± 7.41	22.11 ± 9.62	0.0308	0.0029	0.2520	0.0154
DLCO % predicted, mean ± sd		74.71 ± 11.57	87.81 ± 17.41	79.71 ± 25.65	0.2223	0.0322	0.3959	0.1089
Emphysema presence, n (%)		4 (57)	2 (7)	22 (48)	0.0003	0.0096	0.7040	0.0003
PD15, mean ± sd		−939.00 ± 24.39	−915.89 ± 20.21	−932.11 ± 19.69	0.0020	0.0487	0.4982	0.0015
Bronchiectasis, n (%)		7 (100)	27 (100)	44 (96)	0.4896	0.1801	0.7083	0.4786
Airway Internal Perimeter, mean ± sd		1.07 ± 0.20	1.16 ± 0.36	1.14 ± 0.26	0.7423	0.3639	0.4230	0.7589
Airway Wall Area, mean ± sd		41.40 ± 1.27	41.99 ± 3.99	40.35 ± 3.58	0.1723	0.5201	0.1551	0.0854
Alveolar Macrophage %, mean ± sd		90.64 ± 5.10	85.20 ± 31.02	75.61 ± 28.33	0.2214	0.3927	0.0017	0.1911
BAL Eosinophil %, mean ± sd		0.21 ± 0.57	0.22 ± 1.22	0.51 ± 2.61	0.8335	0.9803	0.4985	0.5187
BAL Lymphocyte %, mean ± sd		7.79 ± 5.60	2.41 ± 2.43	9.72 ± 8.13	8.20E-05	0.0441	0.4425	2.70E-07
BAL Neutrophil %, mean ± sd		1.07 ± 1.17	0.59 ± 0.86	1.44 ± 2.65	0.2607	0.3409	0.5395	0.0467